Neuroprotective Effects of Vapreotide on Tau Transfection–Induced Neurodegeneration

UZUNHİSARCIKLI E., Yerer M. B.

Neurotoxicity Research, cilt.40, sa.6, ss.1824-1837, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s12640-022-00588-2
  • Dergi Adı: Neurotoxicity Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1824-1837
  • Anahtar Kelimeler: Vapreotide, Tau, SH-SY5Y cell line, APOE4 gene, Neurodegeneration, ALZHEIMER-DISEASE, SOMATOSTATIN RECEPTORS, CEREBROSPINAL-FLUID, NEUROPEPTIDE-Y, BRAIN, PHOSPHORYLATION, PROTEIN, NEURONS, HIPPOCAMPUS, OCTAPEPTIDE
  • Kayseri Üniversitesi Adresli: Hayır

Özet

© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by loss of neurons and synapses. The aim of this study was to investigate the effect of somatostatin analogue Vapreotide in an in vitro Alzheimer’s model and its effects based on the relationship between somatostatinergic transmission and neurodegenerative functions. In this study, tau transfection was performed using the MAPT gene cloned into the pcDNA3.1 vector and transfection reagent into the SH-SY5Y cell line. In viability experiments using 10 µM Memantine as a positive control, it was observed that Vapreotide at 50 µM (p < 0.0001) and 100 µM (p < 0.05) had a protective effect on cell viability, 100 µM CYN154806 was found to decrease (p < 0.05) cell viability. It was determined that Vapreotide, decreased the expression levels (50 µM-p < 0.001; 100 µM-p < 0.001; 200 µM-p < 0.0001) and phosphorylation of Tau and p-Tau proteins by western blots. With the qRT-PCR method, it was found that Vapreotide, decreased the BAX/BCL2 (50 µM-p < 0.001; 100 µM-p < 0.01; 200 µM-p < 0.001) expression level and decreased the expression level (50 µM-p < 0.01; 100 µM-p < 0.01; 200 µM-p < 0.001) of the APOE4 gene, which constitutes a genetic risk for AD. This study demonstrates a potential therapeutic role for a somatostatin analogue Vapreotide in Alzheimer’s disease.